TRDA (Entrada Therapeutics) Growth Rank : 0 (As of Mar. 30, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Growth Rank?

Entrada Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Entrada Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Design Center Place, Suite 17-500, Boston, MA, USA, 02210

Website

https://www.entradatx.com

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Executives

Kory James Wentworth	officer: Chief Financial Officer	6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Natarajan Sethuraman	officer: Chief Scientific Officer	6 TIDE STREET, BOSTON MA 02210
Nathan J Dowden	officer: Chief Operating Officer	6 TIDE STREET, BOSTON MA 02210
Dipal Doshi	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Peter S Kim	director	ONE MERCK DRIVE, P.O. BOX 100, WHITEHOUSE STATION X1 08889
Nerissa Kreher	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman	director	C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Bernhardt G Zeiher	director	ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512